Please check your internet connection and try again.
# Rizatriptan
## Overview
Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine. It exhibits faster onset and superior efficacy compared to some other triptans due to its favorable pharmacokinetic profile.
## Primary Indications
Acute treatment of migraine attacks with or without aura in adults and pediatric patients.
## Adult Dosing
* **Initial Dose:** 5 mg or 10 mg orally. Orally disintegrating tablet (ODT) should be placed on the tongue and allowed to dissolve.
* **Maximum Dose:** 30 mg in a 24-hour period.
* **Redosing:** If headache recurs, a second dose may be taken at least 2 hours after the initial dose.
## Pediatric Dosing
* **6 to 17 years (weight ≥40 kg):** 10 mg once.
* **6 to 17 years (weight 20 to <40 kg):** 5 mg once.
* **Maximum Dose:** A single dose per 24 hours. Safety of a second dose in pediatric patients has not been established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; no specific dosing guidelines provided, but consider lower starting doses.
* **Renal Impairment:** Generally not required, but use caution in severe impairment.
* **Propranolol Users:** The dose must be reduced to 5 mg (max 15 mg in 24 hours) as propranolol increases rizatriptan plasma concentrations.
## Contraindications
* History of ischemic heart disease, coronary artery vasospasm (Prinzmetal's angina), or myocardial infarction.
* Uncontrolled hypertension.
* History of stroke or transient ischemic attack (TIA).
* Peripheral vascular disease or ischemic bowel disease.
* Hemiplegic or basilar migraine.
* Use within 24 hours of another triptan or ergotamine-type medication.
* Use within 14 days of monoamine oxidase (MAO) inhibitor therapy.
## Adverse Effects
* **Common:** Dizziness, somnolence, paresthesia, fatigue, dry mouth, and nausea.
* **Serious:** Coronary vasospasm/myocardial ischemia, arrhythmias, serotonin syndrome (when used with other serotonergic agents), and medication-overuse headache.
## Key Drug Interactions
* **MAO Inhibitors:** Risk of severe serotonin syndrome; strictly contraindicated.
* **Propranolol:** Increases rizatriptan exposure; limit dose.
* **SSRI/SNRI Antidepressants:** Theoretical risk of serotonin syndrome; monitor for symptoms (hyperreflexia, agitation, tremor).
## Monitoring
* Monitor cardiovascular status in patients with risk factors for coronary artery disease (consider ECG if high-risk and using for the first time).
* Monitor for signs/symptoms of serotonin syndrome if combined with other serotonergic drugs.
* Assess frequency of use to prevent medication-overuse headache (limit use to ≤10 days per month).
## Clinical Pearls
* ODT formulations do not require water but should be taken with dry hands.
* Efficacy is not significantly different between 5 mg and 10 mg doses for most adults, though 10 mg may be more effective for severe attacks.
* Always ensure the patient is not misdiagnosing cluster headaches or other secondary headache types as migraines before initiation.
***
**Disclaimer:** This information is for educational purposes and reflects general clinical standards. Verify all dosing and contraindications against the current FDA-approved prescribing information and your local institutional protocols before prescribing or administering medication.
